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HIS second international symposium was again jointly 
organized by the Biological and Medicinal Sector of the 
Royal Society of Chemistry (RSC) and by the Croatian 
Chemical Society (CCS), with substantial financial support 
and sponsorship of Fidelta d.o.o. Galapagos Company, 
(http://www.fidelta.eu). The Croatian Academy of Sciences 
supported this meeting as the highest national sponsor. 
Organizing Committee; Gordon Saxty Fidelta), Dave Alker 
(RSC, Biological and Medicinal Sector), and Vitomir Šunjić 
(CCS), and was supported by the Conference Scretariat 
Maggi Churchouse UK, whose experience and meticulous 
work ensured organization to proceed smoothly 
 The international character of this meeting is 
reflected in the line up of 12 speakers from diverse 
universities and companies. Among them were leaders in 
various fields of macrocyclic chemistry and biology who 
presented lectures on the following topics: macrocyclic 
peptides (M. Shapiro, formerly Eli Lilly and Pfizer, Prof. at 
University of Maryland), discovery of new macrocyclic 
antibiotics - Teixobactin (V. Steadman, Selcia), design of 
non-peptidic macrocycles (B. Over, formerly at AstraZeneca, 
now an independent scientist), fascinating new ring expan-
sion method (W. Unsworth, University of York), new 
synthetic anti-tuberculosis agent cyclohexylgriselimycin (E. 
Fontaine, Sanofi), semi-peptidic macrocycles (E. Marsault, 
l’Universite de Sherbrooke), stabilized peptides in drug dis-
covery (A. Mason, GlaxoSmithKline), new opportunities for 
macrocyclic antibiotics (B. Arsić, University of Manchester), 
total synthesis of anti-tumour macrolides (K. Hale, Queen’s 
University, Belfast), semi-synthetic natural products with 
an unexplored mode of action (A. de Blieck, Galapagos), and 
natural-product derived novel chemical space (B. Decorte, 
formerly Janssen Pharm. Companies of Johnson & Johnson, 
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 The meeting was held at the modern research site of 
Fidelta d.o.o. and PLIVA HRVATSKA d.o.o., Prilaz Baruna 
Filipovića 29, HR-10000 Zagreb, Croatia, and ca. 100 partici-
pants were present. It was opened by the chairmen Gordon 
Saxty, chairmen from Fidelta, then Vitomir Šunjić addressed 
the participants in the name of Croatian Chemical Society 
and Croatian Academy of Sciences and Arts. 
 The main objective of Fidelta d.o.o. as the principal 
sponsor and organizer was reached. This research com-
pany in Zagreb has confirmed its competitive position and 
impact on the research field of new, innovative drugs 
derived from natural macrocyclic compounds. As in  
the first symposium, Fidelta has also supported young 
chemists from academic institutions in Croatia by waiv-
ing all their registration fees. This company has emerged 
in the last decade as one of the leading promoters of 
research in chemistry and related fields along the 
complex research path to a new drug entity (NDE),  
and has also enhanced the international reputation of  
its team. 
 
